Coherus Biosciences(CHRS)
$0.41-0.07 (-14.44%)
CHRS
Coherus Biosciences financials statements
$0.41
At close:-0.07 (-14.44%)
Want to see CHRS full AI Analyst Report?
Coherus Biosciences (CHRS) Ratios
1,706 Followers
Coherus Biosciences Ratios
CHRS's free cash flow for Q3 2026 was $-34.02M. For the 2026 fiscal year, CHRS's free cash flow was increased by $0.00 and operating cash flow was $-34.02M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.46 | 1.21 | 1.43 | 2.75 | 3.64 |
| Quick Ratio | 1.43 | 0.96 | 1.24 | 2.47 | 3.42 |
| Cash Ratio | 0.63 | 0.45 | 0.31 | 0.46 | 2.52 |
| Solvency Ratio | -0.84 | 0.06 | -0.28 | -0.47 | -0.49 |
| Operating Cash Flow Ratio | -0.98 | -0.07 | -0.53 | -1.74 | -0.23 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 9.38M | $ -238.94M | $ -347.40M | $ -237.03M | $ 20.71M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.16 | 0.60 | 0.76 | 1.00 | 0.62 |
| Debt-to-Equity Ratio | 0.66 | -2.04 | -2.49 | -3.50 | 4.29 |
| Debt-to-Capital Ratio | 0.40 | 1.96 | 1.67 | 1.40 | 0.81 |
| Long-Term Debt-to-Capital Ratio | 0.38 | 1.99 | 1.69 | 1.41 | 0.81 |
| Financial Leverage Ratio | 4.23 | -3.40 | -3.26 | -3.50 | 6.95 |
| Debt Service Coverage Ratio | -18.91 | 2.24 | -4.77 | -7.87 | -11.35 |
| Interest Coverage Ratio | -19.95 | -4.11 | -5.01 | -7.91 | -11.49 |
| Debt to Market Cap | 0.22 | 1.68 | 1.51 | 0.77 | 0.34 |
| Interest Debt Per Share | 0.41 | 2.59 | 5.54 | 6.61 | 5.86 |
| Net Debt to EBITDA | 0.29 | 2.36 | -1.95 | -1.63 | -0.01 |
| Profitability Margins | |||||
| Gross Profit Margin | 57.94% | 55.97% | 38.19% | 66.79% | 82.36% |
| EBIT Margin | -412.89% | 20.85% | -76.86% | -122.86% | -80.89% |
| EBITDA Margin | -403.58% | 22.83% | -75.39% | -121.10% | -79.83% |
| Operating Profit Margin | -425.72% | -41.83% | -78.99% | -121.72% | -80.80% |
| Pretax Profit Margin | -434.23% | 10.68% | -92.62% | -138.24% | -87.92% |
| Net Profit Margin | -403.80% | 10.68% | -92.48% | -138.24% | -87.92% |
| Continuous Operations Profit Margin | -434.23% | 10.68% | -92.48% | -138.24% | -87.92% |
| Net Income Per EBT | 92.99% | 100.00% | 99.84% | 100.00% | 100.00% |
| EBT Per EBIT | 102.00% | -25.53% | 117.26% | 113.58% | 108.81% |
| Return on Assets (ROA) | -65.92% | 6.36% | -37.78% | -60.68% | -42.26% |
| Return on Equity (ROE) | -279.10% | -21.60% | 122.99% | 212.31% | -293.78% |
| Return on Capital Employed (ROCE) | -154.15% | -67.45% | -68.23% | -75.08% | -51.33% |
| Return on Invested Capital (ROIC) | -151.77% | -66.77% | -67.63% | -74.14% | -50.99% |
| Return on Tangible Assets | -80.29% | 7.22% | -42.64% | -61.43% | -42.48% |
| Earnings Yield | -99.63% | 18.03% | -75.87% | -47.45% | -23.84% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.29 | 2.18 | 0.99 | 1.92 | 2.65 |
| Payables Turnover | 1.79 | 4.13 | 4.51 | 6.08 | 3.56 |
| Inventory Turnover | 5.59 | 1.68 | 2.54 | 1.81 | 1.53 |
| Fixed Asset Turnover | 31.35 | 94.10 | 50.25 | 24.11 | 41.80 |
| Asset Turnover | 0.16 | 0.60 | 0.41 | 0.44 | 0.48 |
| Working Capital Turnover Ratio | 0.68 | 2.64 | 1.33 | 0.62 | 0.62 |
| Cash Conversion Cycle | 20.66 | 296.55 | 432.52 | 332.18 | 273.66 |
| Days of Sales Outstanding | 159.41 | 167.26 | 369.65 | 190.18 | 137.51 |
| Days of Inventory Outstanding | 65.27 | 217.64 | 143.72 | 202.03 | 238.57 |
| Days of Payables Outstanding | 204.02 | 88.36 | 80.85 | 60.03 | 102.41 |
| Operating Cycle | 224.68 | 384.90 | 513.37 | 392.21 | 376.07 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.15 | -0.18 | -1.86 | -3.11 | -0.50 |
| Free Cash Flow Per Share | -1.15 | -0.18 | -1.86 | -3.13 | -0.51 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -611.48 | -118.26 | -29.04 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -611.48 | -118.26 | -29.04 |
| Operating Cash Flow Coverage Ratio | -3.43 | -0.08 | -0.36 | -0.50 | -0.09 |
| Operating Cash Flow to Sales Ratio | -3.28 | -0.08 | -0.68 | -1.14 | -0.11 |
| Free Cash Flow Yield | -81.04% | -12.93% | -55.86% | -39.55% | -3.22% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.98 | 5.52 | -1.32 | -2.11 | -4.19 |
| Price-to-Sales (P/S) Ratio | 4.05 | 0.59 | 1.22 | 2.91 | 3.69 |
| Price-to-Book (P/B) Ratio | 2.80 | -1.20 | -1.62 | -4.47 | 12.32 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.23 | -7.73 | -1.79 | -2.53 | -31.10 |
| Price-to-Operating Cash Flow Ratio | -1.23 | -7.73 | -1.79 | -2.55 | -32.17 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | -0.05 | 0.04 | 1.61 | 0.01 |
| Enterprise Value Multiple | -0.72 | 4.96 | -3.57 | -4.04 | -4.63 |
| Enterprise Value | 122.38M | 302.00M | 691.51M | 1.03B | 1.21B |
| EV to EBITDA | -0.72 | 4.96 | -3.57 | -4.04 | -4.63 |
| EV to Sales | 2.90 | 1.13 | 2.69 | 4.89 | 3.69 |
| EV to Free Cash Flow | -0.88 | -14.77 | -3.95 | -4.24 | -31.15 |
| EV to Operating Cash Flow | -0.88 | -14.77 | -3.95 | -4.28 | -32.22 |
| Tangible Book Value Per Share | 0.12 | -1.62 | -2.82 | -1.85 | 1.25 |
| Shareholders’ Equity Per Share | 0.51 | -1.15 | -2.05 | -1.77 | 1.30 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.35 | 2.33 | 2.73 | 2.72 | 4.33 |
| Net Income Per Share | -1.41 | 0.25 | -2.53 | -3.76 | -3.81 |
| Tax Burden | 0.93 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.05 | 0.51 | 1.21 | 1.13 | 1.09 |
| Research & Development to Revenue | 2.49 | 0.35 | 0.43 | 0.94 | 1.11 |
| SG&A to Revenue | 2.35 | 0.56 | 0.68 | 0.89 | 0.49 |
| Stock-Based Compensation to Revenue | 0.40 | 0.10 | 0.17 | 0.24 | 0.16 |
| Income Quality | -0.82 | -0.72 | 0.74 | 0.83 | 0.13 |
Currency in USD

